I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Attorney Docket No.: 016930-003713US

TOWNSEND and TOWNSEND and CREW LLP

By: Edward Marmas

Edward Masinas

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Nielsen et al.

Application No.: 10/823,932

Filed: April 13, 2004

For: COMBINED TUMOR

SUPPRESSOR GENE THERAPY AND

CHEMOTHERAPY IN THE TREATMENT OF NEOPLASMS

Examiner: Lacourciere, K.

Art Unit: 1635

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37

CFR §1.97 and §1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Also enclosed is a copy of Supplementary Partial European Search Report EP 98910038.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

Nielsen et al.

Application No.: 10/823,932

Page 2

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that <u>no fee is required</u> for submission of this statement.

However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Marlin Centle

Nathan S. Cassell Reg. No. 42,396

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, Eighth Floor San Francisco, California 94111-3834

Tel: 650-326-2400 Fax: 650-326-2422

NSC:bjl 60235739 v1

ZFW

6-11-04

Date

(= 3)		Application Number	10/823,932	
TRANSMITTAL		Filing Date	April 13, 2004	
1 4 2004	FORM	First Named Inventor	Nielsen, Loretta	
(to be us	all correspondence after initial filing	Art Unit	1635	
ato		Examiner Name	Lacourciere, K.	
RADEMA otal Number of	Pages in This Submission	Attorney Docket Number	016930-003713US	
		ENCLOSURES (Check all	that apply)	
Fee Trans	mittal Form	Drawing(s)	After Allowance Communication to Group	
Fe	ee Attached	Licensing-related Papers	Appeal Communication to Board of Appeals and Interferences	
Amendme	nt/Reply	Petition	Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)	
At	ter Final	Petition to Convert to a Provisional Application	Proprietary Information	
A1	fidavits/declaration(s)	Power of Attorney, Revocation Change of Correspondence		
Extension	of Time Request	Terminal Disclaimer	Other Enclosure(s) (please identify below):	
Express A	bandonment Request	Request for Refund	Return Postcard	
Informatio	n Disclosure Statement	CD, Number of CD(s)	PTO/SB/08A and /o8B Form 5 Reference Copies, EP Search Repo	
Certified C	Copy of Priority	Remarks The Commissioner Account 20-1430.	is authorized to charge any additional fees to Dep	
	to Missing Parts/ e Application			
	esponse to Missing Parts der 37 CFR 1.52 or 1.53			
	SIGNAT	URE OF APPLICANT, ATTO	RNEY, OR AGENT	
. Firm	Townsend and Townse	end and Crew LLP		
or Individual name Nathan S. Cassell		f	Reg. No. 42,396	
Signature Maelin Ceall				
Date	6-10-6			
-	CE	RTIFICATE OF TRANSMISS	ION/MAILING	
I hereby certify th	at this correspondence is bei	ing facsimile transmitted to the USPT	O or deposited with the United States Postal Service	

Typed or printed name

Signature

Edward Masinas

Edward Mosmas

Substitute for form 1449B/PTO				Complete if Known		
INITO	384 A TION	DICA	CAPE -	Application Number	10/823,932	
INFORMATION DISCLOSURE OF STATEMENT BY APPLICANT				Filing Date	April 13, 2004	
SIMILIATION WELLIOWING "				First Named Inventor	Nielsen, Loretta	
		ю	י ייטר אַ	Art Unit	1635	
(use as many sheets as hecessary)				Examiner Name	Lacourciere, K.	
Sheet	3	of	C TO ADEMARK	Attorney Docket Number	016930-003713US	

	U.S. PATENT DOCUMENTS+						
		Document Number					
Examiner Cite Initials* No.1	Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
	-						
		•					

			FC	REIGN PA	TENT DOCUM	ENTS		•
Examiner Initials*	Cite No. ¹	Fo	oreign Patent Docume Number ⁴ Kini	nt I Code ⁶ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	
	A	WO	> 95/10514	A1	04-20-1995	Schering Corp.		
	В	WO	95/28948	A1	11-02-1995	Univ. Texas		
		• • • • • • • • • • • • • • • • • • • •						┨╏
			NON P	ATENT LIT	ERATURE DO	CUMENTS	<u>'-</u>	
Examiner Initials *						T ²		
	c A	HARRIS et al., "Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies" <i>J. Natl. Cancer Inst.</i> (1996) <u>88</u> (20):1442-1455.						
	D #	NIELSEN et al., "Combination therapy with the Farnesyl protein transferase inhibitor SCH66336 and SCH58500 (p53 Adenovirus) in preclinical cancer models" Cancer Research (1999) 59:5896-5901.						
	E '	TISHLER et al. "Microtubule-active drugs Taxol, Vinblastine, and Nocodazole increase the levels of transcriptionally active p53" Cancer Research (1995) 55:6021-6025.						
				<u>-</u>				

60235739 v1

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.